Response to Comments: Transurethral Waterjet Ablation of the Prostate

This article is a response to public comments on the Transurethral Waterjet Ablation of the Prostate LCD DL38549 (subsequently L38549). The article itself does not specify clinical coverage criteria, limitations, documentation requirements, or frequency limits; it addresses comments received during the open comment period. The notice period for L38549 begins 2025-10-30 and the LCD becomes effective 2025-12-14; consult the DL38549/L38549 LCD text for the authoritative coverage criteria.